Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 6;11(11):CD015385.
doi: 10.1002/14651858.CD015385.pub2.

Thermal stability and storage of human insulin

Bernd Richter  1 , Brenda Bongaerts  1 , Maria-Inti Metzendorf  1
Affiliations

Thermal stability and storage of human insulin

Bernd Richter et al. Cochrane Database Syst Rev. .

Abstract

Background: Health authorities stress the temperature sensitivity of human insulin, advising protection from heat and freezing, with manufacturers suggesting low-temperature storage for intact vials, and once opened, storage at room temperature for four to six weeks, though usage time and maximum temperature recommendations vary. For human insulin, the recommendations of current shelf life in use may range from 10 to 45 days, and the maximum temperature in use varies between 25 °C and 37 °C. Optimal cold-chain management of human insulin from manufacturing until the point of delivery to people with diabetes should always be maintained, and people with diabetes and access to reliable refrigeration should follow manufacturers' recommendations. However, a growing segment of the diabetes-affected global population resides in challenging environments, confronting prolonged exposure to extreme heat due to the climate crisis, all while grappling with limited access to refrigeration.

Objectives: To analyse the effects of storing human insulin above or below the manufacturers' recommended insulin temperature storage range or advised usage time, or both, after dispensing human insulin to people with diabetes.

Search methods: We used standard, extensive Cochrane search methods. The latest search date was 12 July 2023.

Selection criteria: We included clinical and laboratory studies investigating the storage of human insulin above or below manufacturers' recommended temperature storage range, advised usage time, or both.

Data collection and analysis: We used standard Cochrane methods. We used GRADE to assess the certainty of evidence for the clinical study. Most information emerged from in vitro studies, mainly from pharmaceutical companies. There is no validated risk of bias and certainty of evidence rating for in vitro studies. We thus presented a narrative summary of the results.

Main results: We included 17 eligible studies (22 articles) and additional information from pharmaceutical companies. Pilot clinical study One pilot clinical study investigated temperature conditions for insulin stored for six weeks in an unglazed clay pot with temperatures ranging between 25 °C and 27 °C. The mean fall in plasma glucose in eight healthy volunteers after clay pot-stored insulin injection was comparable to refrigerator-stored insulin injection (very low-certainty evidence). In-vitro studies Nine, three and four laboratory studies investigated storage conditions for insulin vials, insulin cartridges/pens and prefilled plastic syringes, respectively. The included studies reported numerous methods, laboratory measurements and storage conditions. Three studies on prefilled syringes investigating insulin potency at 4 °C up to 23 °C for up to 28 days showed no clinically relevant loss of insulin activity. Nine studies examined unopened vials and cartridges. In studies with no clinically relevant loss of insulin activity for human short-acting insulin (SAI), intermediate-acting insulin (IAI) and mixed insulin (MI) temperatures ranged between 28.9 °C and 37 °C for up to four months. Two studies reported up to 18% loss of insulin activity after one week to 28 days at 37 °C. Four studies examined opened vials and cartridges at up to 37 °C for up to 12 weeks, indicating no clinically relevant reduction in insulin activity. Two studies analysed storage conditions for oscillating temperatures ranging between 25 °C and 37 °C for up to 12 weeks and observed no loss of insulin activity for SAI, IAI and MI. Four studies, two on vials (including one on opened vials), and two on prefilled syringes, investigated sterility and reported no microbial contamination. Data from pharmaceutical companies Four manufacturers (BIOTON, Eli Lilly and Company, Novo Nordisk and Sanofi) provided previously unreleased human insulin thermostability data mostly referring to unopened containers (vials, cartridges). We could not include the data from Sanofi because the company announced the permanent discontinuation of the production of human insulins Insuman Rapid, Basal and Comb 25. BIOTON provided data on SAI after one, three and six months at 25 °C: all investigated parameters were within reference values, and, compared to baseline, loss of insulin activity was 1.1%, 1.0% and 1.7%, respectively. Eli Lilly and Company provided summary data: at below 25 °C or 30 °C SAI/IAI/MI could be stored for up to 25 days or 12 days, respectively. Thereafter, patient in-use was possible for up to 28 days. Novo Nordisk provided extensive data: compared to baseline, after three and six months at 25 °C, loss of SAI activity was 1.8% and 3.2% to 3.5%, respectively. Loss of IAI activity was 1.2% to 1.9% after three months and 2.0% to 2.3% after six months. Compared to baseline, after one, two and three months at 37 °C, loss of SAI activity was 2.2% to 2.8%, 5.7% and 8.3% to 8.6%, respectively. Loss IAI activity was 1.4% to 1.8%, 3.0% to 3.8% and 4.7% to 5.3%, respectively. There was no relevant increase in insulin degradation products observed. Up to six months at 25 °C and up to two months at 37 °C high molecular weight proteins were within specifications. Appearance, visible particles or macroscopy, particulate matter, zinc, pH, metacresol and phenol complied with specifications. There were no data for cold environmental conditions and insulin pumps.

Authors' conclusions: Under difficult living conditions, pharmaceutical companies' data indicate that it is possible to store unopened SAI and IAI vials and cartridges at up to 25 °C for a maximum of six months and at up to 37 °C for a maximum of two months without a clinically relevant loss of insulin potency. Also, oscillating temperatures between 25 °C and 37 °C for up to three months result in no loss of insulin activity for SAI, IAI and MI. In addition, ambient temperature can be lowered by use of simple cooling devices such as clay pots for insulin storage. Clinical studies on opened and unopened insulin containers should be performed to measure insulin potency and stability after varying storage conditions. Furthermore, more data are needed on MI, insulin pumps, sterility and cold climate conditions.

PubMed Disclaimer

Conflict of interest statement

BR: none.

BB: none.

MIM: none.

The authors are editors for the Cochrane Metabolic and Endocrine Disorders group, but they had no role in the editorial processing of this review.

Figures

1
1
Study flow diagram.
2
2
Short‐acting human insulin assay (mean IU/mL with standard deviation) stored at 26.3 °C to 28.9 °C between baseline (month 0) and up to 4 months (data calculated from supplementary appendix Pendsey 2023, insulin reference value 95 IU/mL to 105 IU/mL). IU: international units.
3
3
Intermediate‐acting human insulin assay (mean IU/mL with standard deviation) stored at 26.3 °C to 28.9 °C between baseline (month 0) and up to 4 months (data calculated from supplementary appendix Pendsey 2023, insulin reference value 95 IU/mL to 105 IU/mL). IU: international units.
4
4
Mixed human insulin assay (mean IU/mL with standard deviation) stored at 26.3 °C to 28.9 °C between baseline (month 0) and up to 4 months (data calculated from supplementary appendix Pendsey 2023, insulin reference value 95 IU/mL to 105 IU/mL). IU: international units.
5
5
Short‐acting human insulin assay for vials stored at 25 °C between baseline and up to 12 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
6
6
Short‐acting human insulin assay for cartridges stored at 25 °C between baseline and up to 12 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL) CI: confidence interval; IU: international units.
7
7
Short‐acting human insulin assay for vials stored at 37 °C between baseline and up to 3 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
8
8
Short‐acting human insulin assay for cartridges stored at 37 °C between baseline and up to 3 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
9
9
Short‐acting human insulin assay for vials stored at 5 °C between baseline and up to 24 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
10
10
Short‐acting human insulin assay for cartridges stored at 5 °C between baseline and up to 24 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
11
11
Intermediate‐acting human insulin assay for vials stored at 25 °C between baseline and up to 12 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
12
12
Intermediate‐acting human insulin assay for cartridges stored at 25 °C between baseline and up to 12 months (one batch data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). IU: international units.
13
13
Intermediate‐acting human insulin assay for vials stored at 37 °C between baseline and up to 3 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
14
14
Intermediate‐acting human insulin assay for cartridges stored at 37 °C between baseline and up to 3 months (one batch data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). IU: international units.
15
15
Intermediate‐acting human insulin assay for vials stored at 5 °C between baseline and up to 24 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
16
16
Intermediate‐acting human insulin assay for cartridges stored at 5 °C between baseline and up to 24 months (data from Novo Nordisk, insulin reference value 95 IU/mL to 105 IU/mL). CI: confidence interval; IU: international units.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD015385

References

References to studies included in this review

Al Shaibi 1999 {published data only}
    1. Al Shaibi K, Falata W, Sayes N, Al Shareef M, Al Taweel M, Abozenadah A, et al. Storing insulin in a clay pot in the desert causes no loss of activity: a preliminary report. Annals of Saudi Medicine 1999;19(6):547-9. - PubMed
    1. Arya SC. Insulin storage in a clay pot. Annals of Saudi Medicine 2000;20(5-6):491. [DOI: 10.5144/0256-4947.2000.491] - DOI - PubMed
    1. Tevaarwerk GJ. Reply to "Insulin storage in a clay pot". Annals of Saudi Medicine 2000;20(5-6):491-2. [DOI: 10.5144/0256-4947.2000.491a] - DOI - PubMed
Baechler 2020 {published data only}
    1. Baechler F, Stettler C, Vogt B, Bally L, Groessl M. Concentration and chemical stability of commercially available insulins: a high-resolution mass spectrometry study. Diabetes Technology & Therapeutics 2020;22(4):326-9. [DOI: 10.1089/dia.2019.0412] - DOI - PubMed
Delbeck 2021a {published data only}
    1. Delbeck S, Heise HM. Quality assurance of commercial insulin formulations: novel assay using infrared spectroscopy. Journal of Diabetes Science and Technology 2021;15(4):865-73. [DOI: 10.1177/1932296820913874] - DOI - PMC - PubMed
    1. Delbeck S, Heise HM. Systematic stability testing of insulins as representative biopharmaceuticals using ATR FTIR-spectroscopy with focus on quality assurance. Journal of Biomedical Optics 2021;26(4):043001-16. [DOI: 10.1117/1.JBO.26.4.043007] - DOI - PMC - PubMed
Dunbar 1986 {published data only}
    1. Dunbar JC, Simon FA. Immunologic and biologic evaluation of insulin degradation following prolonged storage in plastic syringes. Pancreas 1986;1(4):317-9. [DOI: 10.1097/00006676-198607000-00004] - DOI - PubMed
Gregory 1991 {published data only}
    1. Gregory R, Edwards S, Yateman NA. Demonstration of insulin transformation products in insulin vials by high-performance liquid chromatography. Diabetes Care 1991;14(1):42-8. [DOI: 10.2337/diacare.14.1.42] - DOI - PubMed
Kaufmann 2021 {published data only}
    1. Kaufmann B, Boulle P, Berthou F, Fournier M, Beran D, Ciglenecki I, et al. Heat-stability study of various insulin types in tropical temperature conditions: new insights towards improving diabetes care. PLOS One 2021;16:1-17. [DOI: 10.1371/journal.pone.0245372] - DOI - PMC - PubMed
    1. Makoni M. Insulin storage without refrigeration. Lancet Diabetes Endocrinology 2021;9(4):202. [DOI: 10.1016/S2213-8587(21)00057-7] - DOI - PubMed
Koffler 1992 {published data only}
    1. Koffler M, Orni-Wasserlauf R, Golani N, Berger SA. Prefilled insulin syringes can be kept sterile for at least 10 days when kept under refrigeration. Journal of Diabetic Complications 1992;6(3):207-8. [DOI: 10.1016/1056-8727(92)90038-m] - DOI - PubMed
Kongmalai 2021 {published data only}
    1. Kongmalai T, Preechasuk L, Junnu S, Manocheewa S, Srisawat C, Sriwijitkamol A. The effect of temperature on the stability of in-use insulin pens. Diabetes 2018;67(Suppl 1):2. [DOI: 10.2337/db18-1008-P] - DOI - PubMed
    1. Kongmalai T, Preechasuk L, Junnu S, Manocheewa S, Srisawat C, Sriwijitkamol A. The effect of temperature on the stability of in-use insulin pens. Experimental and Clinical Endocrinology & Diabetes 2021;129(9):683-8. [DOI: 10.1055/a-1010-5466] - DOI - PubMed
Lull 2013 {published data only}
    1. Lull ME, Piacentino JJ, Traina AN. Stability of U-500 regular insulin in prefilled syringes. Journal of the American Pharmaceutical Association 2013;53(3):304-6. [DOI: 10.1331/JAPhA.2013.12164] - DOI - PubMed
Moses 2019 {published data only}
    1. Moses A, Bjerrum J, Hach M, Waehrens LH, Toft AD. Concentrations of intact insulin concurs with FDA and EMA standards when measured by HPLC in different parts of the distribution cold chain. Journal of Diabetes Science and Technology 2019;13(1):55-9. [DOI: 10.1177/1932296818783783] - DOI - PMC - PubMed
Pendsey 2023 {published data only}
    1. Pendsey S, James S, Garrett TJ, Nord AB, Pendsey S, Malmodin D, et al. Insulin thermostability in a real-world setting. Lancet Diabetes Endocrinology 2023;11(5):310-2. [DOI: 10.1016/S2213-8587(23)00028-1] - DOI - PubMed
Schrader 1985 {published data only}
    1. Schrader E, Pfeiffer EF. The influence of motion and temperature upon the aggregational behavior of soluble insulin formulations investigated by high-performance liquid-chromatography. Journal of Liquid Chromatography 1985;8(6):1139-57. [DOI: 10.1080/01483918508067133] - DOI
Shnek 1998 {published data only}
    1. Shnek DR, Hostettler DL, Bell MA, Olinger JM, Frank BH. Physical stress testing of insulin suspensions and solutions. Journal of Pharmaceutical Sciences 1998;87(11):1459-65. [DOI: 10.1021/js980074x] - DOI - PubMed
Silva 2013 {published data only}
    1. Silva MA, Chuong M, Kerr S, Cabrera A. Stability of two long-acting insulin formulations after 28 days. Journal of Pharmacy Practice & Research 2013;43(1):37-40. [DOI: 10.1002/j.2055-2335.2013.tb00213.x] - DOI
Silva‐Jr 2022 {published data only}
    1. Silva-Jr H, Araújo TS, da Silva Almeida M, Scapin SM, Lima LM. Formation of subvisible particles in commercial insulin formulations. Colloids and Surfaces B: Biointerfaces 2022;216:112566. [DOI: 10.1016/j.colsurfb.2022.112566] - DOI - PubMed
Tarr 1991 {published data only}
    1. Tarr BD, Campbell RK, Workman TM. Stability and sterility of biosynthetic human insulin stored in plastic insulin syringes for 28 days. American Journal of Hospital Pharmacy 1991;48(12):2631-4. - PubMed
Vimalavathini 2009 {published data only}
    1. Vimalavathini R, Gitanjali B. Effect of temperature on the potency & pharmacological action of insulin. Indian Journal of Medical Research 2009;130(2):166-9. - PubMed

References to studies excluded from this review

Albergo 1992 {published data only}
    1. Albergo R, Bunting J, Belsky MK, Fallon JJ Jr. Insulin storage and injection recommendation. Diabetes Care 1992;15(8):1113-4. [DOI: 10.2337/diacare.15.8.1113] - DOI - PubMed
Allen 1982 {published data only}
    1. Allen SC. A cool storage pot for insulin in rural Africa. Medical Journal of Zambia 1982;16(4):83-4. - PubMed
Bishop 1970 {published data only}
    1. Bishop J. Proper storage of insulin preparations. Canadian Medical Association Journal 1970;102(1):104. - PMC - PubMed
Braune 2019 {published data only}
    1. Braune K, Kraemer LA, Weinstein J, Zayani A, Heinemann L. Storage conditions of insulin in domestic refrigerators and when carried by patients: often outside recommended temperature range. Diabetes Technology & Therapeutics 2019;21(5):238-44. [DOI: 10.1089/dia.2019.0046] - DOI - PubMed
Casey 1983 {published data only}
    1. Casey CA. Storage of insulin stirs controversy. Rn National Magazine for Nurses 1983;46(7):73.
Davis 2010 {published data only}
    1. Davis SR, Anderson EA. Creation of a temperature stability database for refrigerated medications. Journal of Pharmacy Practice and Research 2010;40(1):31-5. [DOI: 10.1002/j.2055-2335.2010.tb00722.x] - DOI
Delbeck 2021b {published data only}
    1. Delbeck S, Heise HM. Quality assurance of commercial insulin formulations: novel assay using infrared spectroscopy. Journal of Diabetes Science and Technology 2021;15(4):865-73. [DOI: 10.1177/1932296820913874] - DOI - PMC - PubMed
Dokken 2017 {published data only}
    1. Dokken BB, Rosinko M. Reported insulin pump temperature fluctuations lack clinical relevance. Medical Devices: Evidence and Research 2017;10:43-6. [DOI: 10.2147/MDER.S128526] - DOI - PMC - PubMed
Fisch 1987 {published data only}
    1. Fisch A, Leblanc H, Cisse H, Pichard E, Zirinis P. Stability of ordinary insulins under African climatic conditions. Medecine d'Afrique Noire 1987;34(12):1043-8.
Gill 2000 {published data only}
    1. Gill GV. Viewpoint: stability of insulin in tropical countries. Tropical Medicine & International Health 2000;5(9):666-7. [DOI: 10.1046/j.1365-3156.2000.00617.x] - DOI - PubMed
Gill 2002 {published data only}
    1. Gill G, Price C, English P, Eriksson-Lee J. Traditional clay pots as storage containers for insulin in hot climates. Tropical Doctor 2002;32(4):237-8. [DOI: 10.1177/004947550203200421] - DOI - PubMed
Gilligan 2021 {published data only}
    1. Gilligan MM, Linnes JC, Oettingen JE, Altenor K. From toy to tool: using water beads for insulin storage in Haiti. Pediatric Diabetes 2021;22(5):729-33. [DOI: 10.1111/pedi.13167] - DOI - PubMed
Grajower 2003 {published data only}
    1. Gallo M, Comoglio M, De Micheli A, Monge L, Vespasiani G. Insulin storage in Europe: a comment to Grajower et al., Eli Lilly, and Novo Nordisk. Diabetes Care 2004;27(5):1225-6. [DOI: 10.2337/diacare.27.5.1225] - DOI - PubMed
    1. Grajower MM, Fraser CG, Holcombe JH, Daugherty ML, Harris WC, De Felippis MR, et al. How long should insulin be used once a vial is started? Diabetes Care 2003;26(9):2665-6; discussion 266-9. [DOI: 10.2337/diacare.26.9.2665] - DOI - PubMed
    1. Holcombe JH, Daugherty ML, De Felippis MR. How long should insulin be used once a vial is started? Diabetes Care 2004;27(5):1241-2. [DOI: 10.2337/diacare.27.5.1241] - DOI - PubMed
    1. Molitch ME. How long should insulin be used once a vial is started? Diabetes Care 2004;27(5):1240-1; author reply 1241-2. [DOI: 10.2337/diacare.27.5.1240-a] - DOI - PubMed
Grajower 2014 {published data only}
    1. Flood TM. In response: how long should insulin be used once a vial is opened? Endocrine Practice 2015;21(2):213. - PubMed
    1. Grajower MM. How long can a vial of insulin be used after it is started: where are we 10 years later? Endocrine Practice 2014;20(2):188-90. [DOI: 10.4158/EP13427.CO] - DOI - PubMed
Grant 1946 {published data only}
    1. Grant RL. Loss of potency of commercial insulin stored at room temperature. Federation Proceedings 1946;5(1 Pt 2):181. - PubMed
Grau 1985 {published data only}
    1. Grau U. Chemical stability of insulin in a delivery system environment. Diabetologia 1985;28(7):458-63. - PubMed
Havlova 1966 {published data only}
    1. Havlova M, Nobilis M. Undesirable factors influencing the stability of insulin preparations [NEŽÁDOUCÍ VLIVY PŮSOBÍCÍ NA STABILITU INSULINOVÝCH PREPARÁTŮ]. Ceskoslovenska Farmacie 1966;15(9):504-5. - PubMed
Hearnshaw 2009 {published data only}
    1. Hearnshaw HM. Insulin pumps exposed to heat. Put an indicator on the bottle. BMJ 2009;338:b2009. [DOI: 10.1136/bmj.b2009] - DOI - PubMed
Herr 2014 {published data only}
    1. Herr JK, Keith S, Klug R, Pettis RJ. Characterizing normal-use temperature conditions of pumped insulin. Journal of Diabetes Science and Technology 2014;8(4):850-4. [DOI: 10.1177/1932296814532327] - DOI - PMC - PubMed
Hildebrandt 1986 {published data only}
    1. Hildebrandt R, Jannasch R, Lotz U. On the stability of insulin solutions in syringes. Zeitschrift für Klinische Medizin 1986;41(1):51-3.
Hildebrandt 1987 {published data only}
    1. Hildebrandt R, Rafalski I. Stability and sterility of neutral insulin after opening. Zeitschrift für Klinische Medizin 1987;42(14):1279-81.
Kalra 2012 {published data only}
    1. Kalra S, Kalra B. Storage of insulin in rural areas. Journal of Academy of Medical Sciences 2012;2(2):88-9. [DOI: 10.4103/2249-4855.118669] - DOI
Kasmer 1986 {published data only}
    1. Kasmer RJ, Walker N, Hurlburt F, Rotter G, Shlaes DM, Hostetler C. Sterility of preloaded insulin syringes. American Journal of Infectious Diseases 1986;14(4):180-3. [DOI: 10.1016/0196-6553(86)90098-2] - DOI - PubMed
Keller 2003 {published data only}
    1. Keller KJ. Insulin storage and stability update. South Dakota Journal of Medicine 2003;56(8):303-4. - PubMed
Khurana 2019 {published data only}
    1. Khurana G, Gupta VK. Effect on insulin upon storage in extreme climatic conditions (temperature and pressure) and their preventive measures. Journal of Social Health and Diabetes 2019;7(1):6-10. [DOI: 10.1055/s-0039-1692371] - DOI
Kircher 1990 {published data only}
    1. Kircher W. Drug information. Instructions for storage and administration. Insulin preparations [Arzneimittelanwendung. Aufbewahrungs- und Abgabehinweise. Insulinpräparate]. Medizinische Monatsschrift für Pharmazeuten 1990;13(10):318-20. - PubMed
Kongmalai 2022 {published data only}
    1. Kongmalai T, Orarachin P, Dechates B, Chanphibun P, Junnu S, Srisawat C, et al. The effect of high temperature on the stability of basal insulin in a pen: a randomized controlled, crossover, equivalence trial. BMJ Open Diabetes Research & Care 2022;10(6):1-8. [DOI: 10.1136/bmjdrc-2022003105] - DOI - PMC - PubMed
Kristensen 2011 {published data only}
    1. Kristensen CM, Lilleore SK. Dose accuracy and durability of a durable insulin pen before and after simulated lifetime use. Current Medical Research and Opinion 2011;27(10):1877-83. [DOI: 10.1185/03007995.2011.609885] - DOI - PubMed
Krogh 1928 {published data only}
    1. Krogh A, Hemmingsen AM. The destructive action of heat on insulin solutions. Biochemical Journal 1928;22(5):1231-8. [DOI: 10.1042/bj0221231] - DOI - PMC - PubMed
Levine 1970 {published data only}
    1. Levine R, Mahler R, Moss JM. The management of diabetes. 7. Characteristics of the available insulins. Problems in insulin storage. American Family Physician/GP 1970;2(5):151-63. - PubMed
Lopez 2014 {published data only}
    1. Lopez PE, King BR, Goss PW, Chockalingam G. Bubble formation occurs in insulin pumps in response to changes in ambient temperature and atmospheric pressure but not as a result of vibration. BMJ Open Diabetes Research and Care 2014;2(1):1-4. [DOI: 10.1136/bmjdrc-2014-000036] - DOI - PMC - PubMed
Minuto 2010 {published data only}
    1. Minuto N, Tambroni B, Vannati M, Emmanuele V, Russo C, Lorini R, et al. Diabetic ketoacidosis caused by exposure of insulin to low temperature. Diabetes Technology & Therapeutics 2010;12(9):745-6. [DOI: 10.1089/dia.2010.0055] - DOI - PubMed
Mitchell 2012 {published data only}
    1. Mitchell VD, Porter K, Beatty SJ. Administration technique and storage of disposable insulin pens reported by patients with diabetes. Diabetes Educator 2012;38(5):651-8. [DOI: 10.1177/0145721712450921] - DOI - PubMed
Mokta 2014 {published data only}
    1. Mokta JK, Kalra S. Insulin storage in the Upper Himalayas. Rural and Remote Health 2014;14(2983):1-2. - PubMed
Nassar 2010 {published data only}
    1. Nassar AA, Childs RD, Boyle ME, Jameson KA, Fowke M, Waters KR, et al. Diabetes in the desert: what do patients know about the heat? Journal of Diabetes Science and Technology 2010;4(5):1156-63. [DOI: 10.1177/193229681000400514] - DOI - PMC - PubMed
Ogle 2016 {published data only}
    1. Ogle GD, Abdullah M, Mason D, Januszewski AS, Besancon S. Insulin storage in hot climates without refrigeration: temperature reduction efficacy of clay pots and other techniques. Diabetic Medicine 2016;33(11):1544-53. [DOI: 10.1111/dme.13194] - DOI - PubMed
Oliva 2009 {published data only}
    1. Oliva A, Suarez M, Hernandez JR, Llabres M, Farina JB. Evaluation of non-isothermal methods in stability studies of human insulin pharmaceutical preparations. Journal of Pharmaceutical and Biomedical Analysis 2009;49(4):916-22. [DOI: 10.1016/j.jpba.2009.01.024] - DOI - PubMed
Pendsey 2006 {published data only}
    1. Pendsey S. Keeping insulin cool naturally – the DREAM Trust storage system. Diabetes Voice 2006;51(Special Issue):19.
Perriello 1988 {published data only}
    1. Perriello G, Torlone E, Di Santo S, Fanelli C, De Feo P, Santeusanio F, et al. Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1988;31(11):811-5. [DOI: 10.1007/BF00277482] - DOI - PubMed
Peters 1987 {published data only}
    1. Peters AL, Davidson MB. Effect of storage on action of NPH and regular insulin mixtures. Diabetes Care 1987;10(6):799-800. - PubMed
Pfützner 2016 {published data only}
    1. Pfützner A, Nagar R. Technology solutions to Increase insulin stability in case of extreme weather conditions. Diabetes Technology & Therapeutics 2016;18:A122-3.
Pfützner 2017 {published data only}
    1. Pfützner A, Pesach G, Nagar R. Technology-derived storage solutions for stabilizing insulin in extreme weather conditions I: the ViViCap-1 device. Expert Opinion on Drug Delivery 2017;14(6):709-14. [DOI: 10.1080/17425247.2017.1316261] - DOI - PubMed
Pfützner 2018a {published data only}
    1. Pfützner A, Reeh W, Nagar R, Rose D. The Vivi-Cap stabilizes insulin in extreme temperature conditions. Diabetes Technology & Therapeutics 2018;20:A140-1.
Pfützner 2018b {published data only}
    1. Pfützner A, Reeh W, Strobl S, Rose D. ViViCap – reliable, reusable protection against insulin degradation in high and low ambient temperatures. Diabetes Stoffwechsel und Herz 2018;27(6):307-11.
Pfützner 2018c {published data only}
    1. Pfützner A, Nagar R, Reeh W. A reusable cap for disposable insulin pens protects insulin against temperature-induced degradation. Diabetes 2018;67(Suppl 1):2. [DOI: 10.2337/db18-2281-PUB] - DOI
Pingel 1972 {published data only}
    1. Pingel M, Volund A. Stability of insulin preparations. Diabetes 1972;21(7):805-13. [DOI: 10.2337/diab.21.7.805] - DOI - PubMed
Plager 2017 {published data only}
    1. Plager P, Nurie K, Omann T, Moran A, Piloya T, Bahendeka S, et al. Is insulin diluted when stored in water? Pediatric Diabetes 2017;18(3):237-40. [DOI: 10.1111/pedi.12367] - DOI - PubMed
Pryce 2009 {published data only}
    1. Pryce R. Diabetic ketoacidosis caused by exposure of insulin pump to heat and sunlight. BMJ 2009;338:a2218. [DOI: 10.1136/bmj.a2218] - DOI - PubMed
Puepet 2007 {published data only}
    1. Puepet FH, Mijinyawa BB, Akogu IA. Insulin storage by patients with diabetes in Jos, Nigeria. Journal of Medical Tropics 2007;9:37-40.
Rathod 1985 {published data only}
    1. Rathod M, Saravolatz L, Pohlod D, Whitehouse F, Goldman J. Evaluation of the sterility and stability of insulin from multidose vials used for prolonged periods. Infection Control 1985;6(12):491-4. [DOI: 10.1017/s019594170006361x] - DOI - PubMed
Richards 2013 {published data only}
    1. Richards P, Hillebrandt D. The practical aspects of insulin at high altitude. High Altitude Medicine & Biology 2013;14(3):197-204. [DOI: 10.1089/ham.2013.1020] - DOI - PubMed
Santiago 2002 {published data only}
    1. Santiago OM, Khutoryansky NM, Bilbo CM, Lawton SA, Kristensen CM. Accuracy and precision of the NovoPen 3 insulin delivery device after mechanical and temperature stresses. Endocrine Practice 2002;8(5):351-5. [DOI: 10.4158/EP.8.5.351] - DOI - PubMed
Seyoum 1997 {published data only}
    1. Seyoum B, Abdulkadir J, Feleke Y, Worku Y. Insulin storage by diabetic patients in Ethiopia. Diabetologia 1997;40:2568.
Steil 1988 {published data only}
    1. Steil CF. Insulin storage. Diabetes Educator 1988;14(6):564-5. [DOI: 10.1177/014572178801400624] - DOI - PubMed
Stephenson 1960 {published data only}
    1. Stephenson NR, Romans RG. Thermal stability of insulin made from zinc insulin crystals. Journal of Pharmacy and Pharmacology 1960;12:372-6. [DOI: 10.1111/j.2042-7158.1960.tb12677.x] - DOI - PubMed
Stephenson 2018 {published data only}
    1. Stephenson J. Domestic refrigerators 'may pose risk to insulin quality'. Nursing Times 2018;114(10):46.
Storvick 1968 {published data only}
    1. Storvick WO, Henry HJ. Effect of storage temperature on stability of commercial insulin preparations. Diabetes 1968;17(8):499-502. [DOI: 10.2337/diab.17.8.499] - DOI - PubMed
TCTR20210611002 {published data only}
    1. TCTR20210611002. Efficacy of in-used insulin pen kept at 37 Celsius for 21 days on mean daily glucose measured by continuous glucose monitoring compare with the effect of newly used insulin pen, the equivalence trial. www.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20210611002 (accessed 3 January 2022).
Thirunavukkarasu 1968 {published data only}
    1. Thirunavukkarasu K. Soluble insulin in the tropics. Ceylon Medical Journal 1968;13(3):150-3. - PubMed
Vereshchetin 2016 {published data only}
    1. Vereshchetin P, McCann TW Jr, Ojha N, Venugopalan R, Levy BL. Comparison of rechargeable versus battery-operated insulin pumps: temperature fluctuations. Medical Devices: Evidence and Research 2016;9:371-6. [DOI: 10.2147/MDER.S116666] - DOI - PMC - PubMed
Virmani 2020 {published data only}
    1. Virmani A, Avni TC. A case for expanding thermochromic vial monitor technology to insulin and other biologics. Indian Pediatrics 2020;57(1):17-9. - PubMed
Westphal 2010 {published data only}
    1. Westphal SA, Childs RD, Seifert KM, Boyle ME, Fowke M, Iniguez P, et al. Managing diabetes in the heat: potential issues and concerns. Endocrine Practice 2010;16(3):506-11. [DOI: 10.4158/EP09344.RA] - DOI - PubMed
Yun‐Chu 2017 {published data only}
    1. Yun-Chu C, Francoise K, Karen EJ, Asel S. Thermal stability, storage, release and delivery of insulin – a protection through sol-gel tailored silica. European Biophysics Journal 2017;46(Suppl 1):S320.
Zell 1983 {published data only}
    1. Zell M, Paone RP. Stability of insulin in plastic syringes. American Journal of Hospital Pharmacy 1983;40(4):637-8. - PubMed
Zhao 2015 {published data only}
    1. Zhao Xiaolei, Zheng Silin. Research progress on period of validity and storage conditions of opened insulin [胰岛素开启后有效期和贮藏条件的研究进展]. Chinese Nursing Research 2015;29(11A):3848-50. [DOI: 10.3969/j.issn.1009-6493.2015.31.003] - DOI

Additional references

ADA 2003
    1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5-20. - PubMed
ADA 2017
    1. American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care 2017;40(Suppl 1):S11-33.
ADA 2021
    1. American Diabetes Association. Insulin storage and syringe safety. www.diabetes.org/healthy-living/medication-treatments/insulin-other-inje... (accessed 15 October 2021).
Ahmad 2003
    1. Ahmad A, Millett IS, Doniach S, Uversky VN, Fink AL. Partially folded intermediates in insulin fibrillation. Biochemistry 2003;42(39):11404-16. [DOI: 10.1016/j.actbio.2013.03.002] - DOI - PubMed
Arora 2004
    1. Arora A, Ha C, Park CB. Insulin amyloid fibrillation at above 100 degrees C: new insights into protein folding under extreme temperatures. Protein Science 2004;13(9):2429-36. - PMC - PubMed
Atwoli 2021
    1. Atwoli L, Baqui AH, Benfield T, Bosurgi R, Godlee F, Hancocks S, et al. Call for emergency action to limit global temperature Increases, restore biodiversity, and protect health. New England Journal of Medicine 2021;385(12):1134-7. [DOI: 10.1056/NEJMe2113200] - DOI - PubMed
Bahendeka 2019
    1. Bahendeka S, Kaushik R, Swai AB, Otieno F, Bajaj S, Kalra S, et al. EADSG guidelines: insulin storage and optimisation of injection technique in diabetes management. Diabetes Therapy 2019;10(2):341-66. [DOI: 10.1007/s13300-019-0574-x] - DOI - PMC - PubMed
Basu 2019
    1. Basu S, Yudkin JS, Kehlenbrink S, Davies JI, Wild SH, Lipska KJ, et al. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinology 2019;7(1):25-33. [DOI: 10.1016/S2213-8587(18)30303-6] - DOI - PubMed
Beran 2006
    1. Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. Lancet 2006;368(9548):1689-95. [DOI: 10.1016/S0140-6736(06)69704-3] - DOI - PubMed
Beran 2016
    1. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinology 2016;4(3):275-85. [DOI: 10.1016/S2213-8587(15)00521-5] - DOI - PubMed
Brange 1987
    1. Brange J. Galenics of Insulin. Heidelberg: Springer-Verlag, 1987.
Brange 1997
    1. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fibrillation. Journal of Pharmaceutical Sciences 1997;86(5):517-25. [DOI: 10.1021/js960297s] - DOI - PubMed
Burki 2022
    1. Burki T. Hot topics on insulin access: the issue of thermostability. Lancet. Diabetes & Endocrinology 2022;10(6):389-90. [DOI: 10.1016/ S2213-8587(22)00140-1] - PubMed
Calo 2016
    1. Calo N, Ramadori P, Sobolewski C, Romero Y, Maeder C, Fournier M, et al. Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut 2016;65(11):1871-81. [DOI: 10.1136/gutjnl-2015-310822] - DOI - PubMed
Chance 1993
    1. Chance RE, Frank BH. Research, development, production, and safety of biosynthetic human insulin. Diabetes Care 1993;16(Suppl 3):133-42. [DOI: 10.2337/diacare.16.3.133] - DOI - PubMed
Danne 2018
    1. Danne T, Phillip M, Buckingham BA, Jarosz-Chobot P, Saboo B, Urakami T, et al. ISPAD clinical practice consensus guidelines 2018: insulin treatment in children and adolescents with diabetes. Pediatric Diabetes 2018;19(Suppl 27):115-35. [DOI: 10.1111/pedi.12718] - DOI - PubMed
Delbeck 2020a
    1. Delbeck S, Krolinski A, Dederich Y, Stoppelkamp S, Heise HM. A novel approach for the assessment of insulin potency by glycemic monitoring of an insulin-dependent human cell line. Journal of Diabetes Science and Technology 2020;14(3):691-2. [DOI: 10.1177/1932296819895541] - DOI - PMC - PubMed
Delbeck 2020b
    1. Delbeck S, Heise HM. FT-IR versus EC-QCL spectroscopy for biopharmaceutical quality assessment with focus on insulin-total protein assay and secondary structure analysis using attenuated total reflection. Analytical and Bioanalytical Chemistry 2020;412(19):4647-58. [DOI: 10.1007/s00216-020-02718-1] - DOI - PMC - PubMed
Derewenda 1989
    1. Derewenda U, Derewenda Z, Dodson GG, Hubbard RE, Korber F. Molecular structure of insulin: the insulin monomer and its assembly. British Medical Bulletin 1989;45(1):4-18. [DOI: 10.1093/oxfordjournals.bmb.a072320] - DOI - PubMed
Devi 2021
    1. Devi S. Cold comfort: getting insulin to those who need it. Lancet 2021;398(10313):1791. - PubMed
Ebi 2021
    1. Ebi KL, Capon A, Berry P, Broderick C, Dear R, Havenith G, et al. Hot weather and heat extremes: health risks. Lancet 2021;398(10301):698-708. [DOI: 10.1016/S0140-6736(21)01208-3] - DOI - PubMed
European Pharmacopoeia 2023
    1. European Pharmacopoeia (Ph. Eur), 11th Edition. Strasbourg: European Pharmacopoeia Commission, European Directorate for the Quality of Medicines (EDQM); 2023.
Farid 1989
    1. Farid NA, Atkins LM, Becker GW, Dinner A, Heiney RE, Miner DJ, et al. Liquid chromatographic control of the identity, purity and "potency" of biomolecules used as drugs. Journal of Pharmaceutical and Biomedical Analysis 1989;7(2):185-8. [DOI: 10.1016/0731-7085(89)80082-2] - DOI - PubMed
Fisher 1986
    1. Fisher BV, Smith D. HPLC as a replacement for the animal response assays for insulin. Journal of Pharmaceutical and Biomedical Analysis 1986;4(3):377-87. [DOI: 10.1016/0731-7085(86)80059-0] - DOI - PubMed
Flemyng 2023
    1. Flemyng E, Moore TH, Boutron I, Higgins JP, Hróbjartsson A, Nejstgaard CH, et al. Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane. BMJ Evidence-Based Medicine 2023;28:260-6. [DOI: 10.1136/bmjebm-2022-112102] - DOI - PubMed
Flood 2015
    1. Flood TM. In response: how long should insulin be used once a vial is opened? Endocrine Practice 2015;21(2):213. - PubMed
Fullerton 2018
    1. Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2018, Issue 12. Art. No: CD013228. [DOI: 10.1002/14651858.CD013228] - DOI - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 29 June 2023. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Grajower 2003
    1. Grajower MM, Fraser CG, Holcombe JH, Daugherty ML, Harris WC, De-Felippis MR, et al. How long should insulin be used once a vial is started? Diabetes Care 2003;26(9):2665-9. [DOI: 10.2337/diacare.26.9.2665] - DOI - PubMed
Grajower 2014
    1. Grajower M. How long can a vial of insulin be used after it is started: where are we 10 years later? Endocrine Practice 2014;20(2):188-90. [DOI: 10.4158/EP13427.CO] - DOI - PubMed
Groenning 2009
    1. Groenning M, Frokjaer S, Vestergaard B. Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process. Current Protein & Peptide Science 2009;10(5):509-28. [DOI: 10.2174/138920309789352038] - DOI - PubMed
Heinemann 2021
    1. Heinemann L, Braune K, Carter A, Zayani A, Krämer LA. Insulin storage: a critical reappraisal. Journal of Diabetes Science and Technology 2021;15(1):147-59. [DOI: 10.1177/1932296819900258] - DOI - PMC - PubMed
Hemmingsen 2021
    1. Hemmingsen B, Metzendorf MI, Richter B. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus. Cochrane Database of Systematic Reviews 2021, Issue 3. Art. No: CD013498. [DOI: 10.1002/14651858.CD013498.pub2] - DOI - PMC - PubMed
Herr 2014
    1. Herr JK, Keith S, Klug R, Pettis RJ. Characterizing normal-use temperature conditions of pumped insulin. Journal of Diabetes Science and Technology 2014;8(4):850-4. [DOI: 10.1177/1932296814532327] - DOI - PMC - PubMed
Higgins 2022a
    1. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.
Higgins 2022b
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.
Huus 2005
    1. Huus K, Havelund S, Olsen HB, de Weert M, Frokjaer S. Thermal dissociation and unfolding of insulin. Biochemistry 2005;44(33):11171-7. [DOI: 10.1021/bi0507940] - DOI - PubMed
Huus 2006
    1. Huus K, Havelund S, Olsen HB, de Weert M, Frokjaer S. Chemical and thermal stability of insulin: effects of zinc and ligand binding to the insulin zinc-hexamer. Pharmaceutical Research 2006;23(11):2611-20. [DOI: 10.1007/s11095-006-9098-y] - DOI - PubMed
IDF 2021
    1. International Diabetes Federation. IDF Diabetes Atlas 2021 (IDF Atlas 10th edition). diabetesatlas.org/en/resources (accessed 18 December 2021).
Kaufmann 2021
    1. Kaufmann B, Boulle P, Berthou F, Fournier M, Beran D, Ciglenecki I, et al. Heat-stability study of various insulin types in tropical temperature conditions: new insights towards improving diabetes care. PLOS One 2021;16(2):e0245372. [DOI: 10.1371/journal.pone.0245372] - DOI - PMC - PubMed
Khurana 2019
    1. Khurana G, Gupta VK. Effect on insulin upon storage in extreme climatic conditions (temperature and pressure) and their preventive measures. Journal of Social Health and Diabetes 2019;7(1):6-10. [DOI: 10.1055/s-0039-1692371] - DOI
Kurouski 2012
    1. Kurouski D, Washington J, Ozbil M, Prabhakar R, Shekhtman A, Lednev IK. Disulfide bridges remain intact while native insulin converts into amyloid fibrils. PLOS One 2012;7(6):e36989. [DOI: 10.1371/journal.pone.0036989] - DOI - PMC - PubMed
Lilly 2023
    1. Humulin R – insulin human injection, solution. uspl.lilly.com/humulinru100/humulinru100.html#ug0 (assessed 25 June 2023).
Mori 2021
    1. Mori W, Kaneko N, Nakanishi A, Zako T, Masumoto J. Insulin amyloid fibrils interact directly with the NLRP3, resulting in inflammasome activation and pyroptotic cell death. International Journal of Immunopathology and Pharmacology 2021;35:1-7. [DOI: 10.1177/20587384211038357] - DOI - PMC - PubMed
Novo Nordisk 2020a
    1. Insulatard: EPAR – product information. www.ema.europa.eu/documents/product-information/insulatard-epar-product-... (assessed 29 June 2023).
Novo Nordisk 2020b
    1. Actrapid: EPAR – product information. www.ema.europa.eu/documents/product-information/actrapid-epar-product-in... (assessed 29 June 2023).
Ogle 2016
    1. Ogle GD, Abdullah M, Mason D, Januszewski AS, Besançon S. Insulin storage in hot climates without refrigeration: temperature reduction efficacy of clay pots and other techniques. Diabetic Medicine 2016;33(11):1544-53. [DOI: 10.1111/dme.13194] - DOI - PubMed
Ohno 2019
    1. Ohno Y, Seki T, Kojima Y, Miki R, Egawa Y, Hosoya O, et al. Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations. Journal of Pharmaceutical Health Care and Sciences 2019;5:22. [DOI: 10.1186/s40780-019-0151-5] - DOI - PMC - PubMed
Page 2021
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. [DOI: 10.1136/bmj.n71] - DOI - PMC - PubMed
Pande 2022
    1. Pande AR, Thakur AK. Perceptions of alternative methods of insulin storage: an ethical dilemma. Lancet. Diabetes & Endocrinology 2022;10(8):558. - PubMed
Pingel 1972
    1. Pingel M, Volund A. Stability of insulin preparations. Diabetes 1972;21(7):805-13. [DOI: 10.2337/diab.21.7.805] - DOI - PubMed
Pryce 2009
    1. Pryce R. Diabetic ketoacidosis caused by exposure of insulin pump to heat and sunlight. BMJ 2009;338:a2218. [DOI: 10.1136/bmj.a2218] - DOI - PubMed
Quijal‐Zamorano 2021
    1. Quijal-Zamorano M, Martinez-Solanas E, Achebak H, Petrova D, Robine JM, Herrmann FR, et al. Seasonality reversal of temperature attributable mortality projections due to previously unobserved extreme heat in Europe. Lancet Planet Health 2021;5(9):e573. [DOI: 10.1016/S2542-5196(21)00211-4] - DOI - PubMed
Sanofi 2023a
    1. Editor. Sanofi to discontinue Insuman® insulins over upcoming months. diabetestimes.co.uk/sanofi-to-discontinue-insuman-insulins-over-upcoming... (assessed 11 June 2023).
Sanofi 2023b
    1. Information letter from Sanofi-Aventis Deutschland GmbH on the worldwide discontinuation of the production of the medicinal products Insuman basal, Insuman rapid and Insuman comb25 [Informationsschreiben der Sanofi-Aventis Deutschland GmbH zur weltweiten Einstellung der Produktion der Arzneimittel INSUMAN BASAL, INSUMAN RAPID und INSUMAN COMB25]. www.bfarm.de/SharedDocs/Arzneimittelzulassung/Lieferengpaesse/DE/2023/in... (assessed 29 June 2023).
Schünemann 2022
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.
Semlitsch 2020
    1. Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No: CD005613. [DOI: 10.1002/14651858.CD005613.pub4] - DOI - PMC - PubMed
Shnek 1998
    1. Shnek DR, Hostettler DL, Bell MA, Olinger JM, Frank BH. Physical stress testing of insulin suspensions and solutions. Journal of Pharmaceutical Sciences 1998;87(11):1459-65. [DOI: 10.1021/js980074x] - DOI - PubMed
Smith 1985
    1. Smith HW Jr, Atkins LM, Binkley DA, Richardson WG, Miner DJ. A universal HPLC determination of insulin potency. Journal of Liquid Chromatography 1985;8(3):419-39.
Sterne 2016
    1. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. [DOI: 10.1136/bmj.i4919] - DOI - PMC - PubMed
Storvick 1968
    1. Storvick WO, Henry HJ. Effect of storage temperature on stability of commercial insulin preparations. Diabetes 1968;17(8):499-502. [DOI: 10.2337/diab.17.8.499] - DOI - PubMed
Sun 2022
    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice 2022;183:109119. [DOI: 10.1016/j.diabres.2021.109119] - DOI - PMC - PubMed
Taerahkun 2022
    1. Taerahkun S, Sriphrapradang C. Efficacy of alternative cooling devices used for insulin storage without refrigeration under hot-humid environment. Annals of Medicine 2022;54(1):1118-25. [DOI: 10.1080/07853890.2022.2067355] - DOI - PMC - PubMed
USP 2016
    1. US Pharmacopeia. Insulin Human Drug Products 100 IU/ml. Rockville, MD: United States Pharmacopeial Convention; 2016.
Vimalavathini 2009
    1. Vimalavathini R, Gitanjali B. Effect of temperature on the potency & pharmacological action of insulin. Indian Journal of Medical Research 2009;130(2):166-9. - PubMed
Weiss 2013
    1. Weiss M. Design of ultra-stable insulin analogues for the developing world. Journal of Health Specialities 2013;1(2):59-70.
Westphal 2010
    1. Westphal SA, Childs RD, Seifert KM, Boyle ME, Fowke M, Iniguez P, et al. Managing diabetes in the heat: potential issues and concerns. Endocrine Practice 2010;16(3):506-11. [DOI: 10.4158/EP09344.RA] - DOI - PubMed
WHO 1999
    1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. In: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva (Switzerland): World Health Organization, 1999:1-59.
WHO 2011
    1. WHO Technical Report Series, No 961. Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products. www.who.int/medicines/areas/quality_safety/quality_assurance/ModelGuidan... (accessed 15 October 2021).
WHO 2020
    1. World Health Organization. Diagnosis and management of type 2 diabetes. apps.who.int/iris/rest/bitstreams/1274478/retrieve (accessed 11 August 2023).
WHO EML 2021
    1. World Health Organization. World Health Organization Model List of Essential Medicines – 22nd List (2021). apps.who.int/iris/rest/bitstreams/1374779/retrieve (accessed 15 October 2021).

References to other published versions of this review

Richter 2022
    1. Richter B, Bongaerts B, Metzendorf M-I. Thermal stability and storage of human insulin. Cochrane Database of Systematic Reviews 2022, Issue 1. Art. No: CD015385. [DOI: 10.1002/14651858.CD015385] - DOI - PMC - PubMed

Publication types

LinkOut - more resources